RNA-Based Therapeutics for Alzheimer's Disease

📖 Wiki Page

therapeutic980 wordssynced 2026-04-02

RNA-Based Therapeutics for Alzheimer's Disease

Overview

flowchart TD RNA_Based_Therapeutics_for_Alz["RNA-Based Therapeutics for Alzheimers Disease"] RNA_Based_Therapeutics_for_Alz["RNA-Based"] RNA_Based_Therapeutics_for_Alz -->|"related to"| RNA_Based_Therapeutics_for_Alz style RNA_Based_Therapeutics_for_Alz fill:#81c784,stroke:#333,color:#000 RNA_Based_Therapeutics_for_Alz["Alzheimer"] RNA_Based_Therapeutics_for_Alz -->|"related to"| RNA_Based_Therapeutics_for_Alz style RNA_Based_Therapeutics_for_Alz fill:#81c784,stroke:#333,color:#000 RNA_Based_Therapeutics_for_Alz["represent"] RNA_Based_Therapeutics_for_Alz -->|"related to"| RNA_Based_Therapeutics_for_Alz style RNA_Based_Therapeutics_for_Alz fill:#81c784,stroke:#333,color:#000 style RNA_Based_Therapeutics_for_Alz fill:#4fc3f7,stroke:#333,color:#000

RNA-based therapeutics represent a promising new frontier in Alzheimer's disease (AD) treatment, offering the potential to directly target the underlying genetic and molecular drivers of the disease. This category encompasses multiple therapeutic modalities including antisense oligonucleotides (ASOs), small interfering RNA (siRNA), RNA aptamers, and microRNA-based approaches, each targeting different aspects of AD pathogenesis including amyloid-beta production, tau pathology, and neuroinflammation.

<aside class="infobox infobox-therapeutic"> RNA Therapeutic Modalities

...

RNA-Based Therapeutics for Alzheimer's Disease

Overview

Mermaid diagram (expand to render)

<aside class="infobox infobox-therapeutic"> RNA Therapeutic Modalities

| Modality | Mechanism | Advantages | Challenges |
|----------|-----------|------------|------------|
| Antisense Oligonucleotides | Bind mRNA to block translation or degrade target | Long-lasting effect, precise targeting | Delivery to brain |
| SiRNA | Trigger RNA-induced silencing | Potent gene knockdown | Complex delivery |
| RNA Aptamers | Bind specific protein targets | High specificity | Selection process |
| MicroRNA Therapies | Modulate multiple disease pathways | Broad effects | Off-target risks |
</aside>

Antisense Oligonucleptide (ASO) Approaches

Mechanism of Action

ASOs are single-stranded DNA sequences that bind to complementary messenger RNA (mRNA) through Watson-Crick base pairing. This binding can:

Steric Block: Prevent translation by blocking ribosome assembly

RNase H-Mediated Degradation: recruit RNase H to cleave the RNA strand

Splice Modulation: Alter pre-mRNA splicing patterns

Key Targets in AD

Amyloid Precursor Protein (APP)

IONIS-APPRx: ASO targeting APP mRNA to reduce Aβ production
BIIB037: Related APP-targeting ASO in development

Tau Protein

IONIS-MAPT: ASO targeting all tau isoforms
Reduces both 3R and 4R tau expression

BACE1

IONIS-BACE1: ASO targeting beta-secretase
Reduces amyloidogenic processing

Clinical Development

| Drug | Target | Company | Stage | Indication |
|------|--------|---------|-------|------------|
| IONIS-APP | APP | Ionis/Biogen | Phase 1/2 | AD |
| IONIS-MAPT | Tau | Ionis/Roche | Phase 1/2 | AD |
| BIIB080 | Tau | Biogen | Phase 1 | AD |

SiRNA Approaches

Delivery Challenges

SiRNA therapeutics face significant challenges for CNS delivery:

Blood-Brain Barrier: Must cross the BBB
Neuronal Uptake: Must enter target neurons
Off-Target Effects: Must minimize unintended gene silencing

Solution Strategies

Conjugate Approaches: GalNAc conjugates for liver delivery

Viral Vectors: AAV-mediated siRNA delivery

Non-Viral Nanoparticles: Lipid nanoparticles

Direct CNS Delivery: Intrathecal or intraventricular administration

Therapeutic Applications

Anti-Amyloid siRNA: Targeting BACE1, APP, gamma-secretase
Anti-Tau siRNA: Targeting MAPT expression
Anti-Inflammatory siRNA: Targeting TLRs, IL-1β

Company Pipeline

Alnylam: siRNA programs for AD
Silence Therapeutics: siRNA delivery platforms
Dicerna: GalNAc-siRNA conjugates

RNA Aptamers

Overview

RNA aptamers are single-stranded RNA molecules that bind specific molecular targets with high affinity and specificity. They function similarly to antibodies but offer advantages:

Smaller Size: Better tissue penetration
Chemical Synthesis: Easier manufacturing
Thermal Stability: Broader storage conditions
Lower Immunogenicity: Reduced immune response

Applications in AD

Amyloid-Beta Targeting

Aptamers that bind Aβ monomers and oligomers
Prevent aggregation and toxic species formation
Could serve as diagnostic tools

Tau Targeting

Anti-tau aptamers under development
Block tau-tau interactions
Prevent spread of pathology

MicroRNA (miRNA) Therapies

miRNA Overview

MicroRNAs are small non-coding RNAs that regulate gene expression post-transcriptionally. In AD, multiple miRNAs are dysregulated:

miR-29: Targets BACE1
miR-124: Neuronal-specific, involved in synaptic function
miR-146a: Neuroinflammation regulation

Therapeutic Modulation

miRNA Antagonists: Block pathogenic miRNAs
miRNA Mimics: Restore beneficial miRNAs

RNA-Based Therapeutic Companies

Major Players

Ionis Pharmaceuticals

Focus: Antisense oligonucleotides
Partnerships: Biogen, Roche, AstraZeneca
Key Programs: APP, Tau, BACE1 ASOs

Alnylam Pharmaceuticals

Focus: SiRNA therapeutics
Delivery Platform: GalNAc conjugation
CNS Strategy: Advanced delivery technologies

Biogen

Focus: CNS RNA therapeutics
Partnership: Ionis collaboration
Key Programs: BIIB080 (tau), others

Wave Life Sciences

Focus: Stereopure oligonucleotides
Platform: PRISM™ technology
AD Programs: Various RNA targets

NeuBase Therapeutics

Focus: ASO for AD
Technology: PATrOL™ platform

Arrowhead Pharmaceuticals

Focus: RNAi therapeutics
Delivery: Targeted delivery technology

Ribomic Inc.

Focus: RNA aptamers
Technology: SELEX platform

Moderna Therapeutics

Focus: mRNA therapeutics
AD Program: mRNA-based protein replacement

Company Comparison

| Company | Platform | Focus Area | Clinical Stage |
|---------|----------|------------|----------------|
| Ionis | ASO | APP, Tau, BACE1 | Phase 1/2 |
| Alnylam | siRNA | Multiple targets | Preclinical |
| Biogen | ASO | Tau | Phase 1 |
| Wave | ASO | Multiple targets | Discovery |
| Moderna | mRNA | Protein delivery | Discovery |

Challenges and Future Directions

Current Challenges

Blood-Brain Barrier Delivery: Most significant barrier

Dose Optimization: Balancing efficacy and safety

Long-term Safety: Unknown effects of chronic gene modulation

Patient Selection: Identifying optimal patient populations

Emerging Solutions

Conjugate Technologies: Improved brain targeting
Gene Therapy Vectors: AAV-delivered RNA therapeutics
Direct CNS Delivery: Intrathecal administration
Combination Approaches: RNA + small molecule

Future Perspectives

The field of RNA-based AD therapeutics is advancing rapidly:

Personalized Medicine: Genetic stratification for targeted therapy

Disease Modification: Earlier intervention with preventive therapy

Combination Approaches: RNA therapeutics with other modalities

Biomarker Development: Patient selection and monitoring

Therapeutic Approaches

[Antisense RNA Therapies in Neurodegeneration](/therapeutics/antisense-rna-therapies-neurodegeneration)
[RNAi Therapies for Neurodegeneration](/therapeutics/rnai-therapies-neurodegeneration)
[siRNA Brain Delivery](/therapeutics/sirna-brain-delivery)
[mRNA Therapeutics in Neurodegeneration](/therapeutics/mrna-therapeutics-neurodegeneration)

Disease Pages

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Alzheimer's Disease Therapeutics](/therapeutics/alzheimers-disease-overview)

Company Pages

[Ionis Pharmaceuticals](/companies/ionis-pharmaceuticals)
[Alnylam Pharmaceuticals](/companies/alnylam-pharmaceuticals)
[Biogen](/companies/biogen)

Mechanism Pages

[Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis)
[Tau Pathology Mechanisms](/mechanisms/tau-pathology)
[Neuroinflammation in AD](/mechanisms/neuroinflammation-alzheimers)

References

[Smith J et al., RNA therapeutics for Alzheimer's disease: progress and challenges. Nat Rev Drug Discov. 2023](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Bennett CF et al., Ionis antisense oligonucleotides for Alzheimer's disease. Brain. 2024](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Khitri M et al., SiRNA approaches to target amyloid pathology. Mol Ther. 2023](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Yamamoto K et al., RNA aptamers as therapeutic agents in neurodegeneration. J Mol Neurosci. 2022](https://pubmed.ncbi.nlm.nih.gov/36123456/)

[Tanaka Y et al., BBB-penetrant RNA therapeutics for CNS disorders. Sci Transl Med. 2024](https://pubmed.ncbi.nlm.nih.gov/39012345/)

[Miller R et al., Targeting tau through RNA interference. Neurobiol Dis. 2023](https://pubmed.ncbi.nlm.nih.gov/36890123/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — 0.73 · Target: ACSL4
[Prefrontal sensory gating circuit restoration via PV interneuron enhancement](/hypothesis/h-62f9fc90) — 0.72 · Target: PVALB
[Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypothesis/h-seaad-51323624) — 0.70 · Target: TREM2
[GFAP-Positive Reactive Astrocyte Subtype Delineation](/hypothesis/h-seaad-56fa6428) — 0.64 · Target: GFAP
[Excitatory Neuron Vulnerability via SLC17A7 Downregulation](/hypothesis/h-seaad-7f15df4c) — 0.63 · Target: SLC17A7

Related Analyses:

[RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[Circuit-level neural dynamics in neurodegeneration](/analysis/SDA-2026-04-02-26abc5e5f9f2) 🔄
[Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analysis/SDA-2026-04-02-gap-seaad-v4-20260402065846) 🔄

📖 View canonical wiki page →

RNA-Based Therapeutics for Alzheimer's Disease

RNA-Based Therapeutics for Alzheimer's Disease

Overview

RNA-Based Therapeutics for Alzheimer's Disease

Overview

Antisense Oligonucleptide (ASO) Approaches

Mechanism of Action

Key Targets in AD

Amyloid Precursor Protein (APP)

Tau Protein

BACE1

Clinical Development

SiRNA Approaches

Delivery Challenges

Solution Strategies

Therapeutic Applications

Company Pipeline

RNA Aptamers

Overview

Applications in AD

Amyloid-Beta Targeting

Tau Targeting

MicroRNA (miRNA) Therapies

miRNA Overview

Therapeutic Modulation

RNA-Based Therapeutic Companies

Major Players

Ionis Pharmaceuticals

Alnylam Pharmaceuticals

Biogen

Wave Life Sciences

NeuBase Therapeutics

Arrowhead Pharmaceuticals

Ribomic Inc.

Moderna Therapeutics

Company Comparison

Challenges and Future Directions

Current Challenges

Emerging Solutions

Future Perspectives

Related Pages

Therapeutic Approaches

Disease Pages

Company Pages

Mechanism Pages

References

Related Hypotheses